MY184103A - Novel cho integration sites and uses thereof - Google Patents

Novel cho integration sites and uses thereof

Info

Publication number
MY184103A
MY184103A MYPI2017701254A MYPI2017701254A MY184103A MY 184103 A MY184103 A MY 184103A MY PI2017701254 A MYPI2017701254 A MY PI2017701254A MY PI2017701254 A MYPI2017701254 A MY PI2017701254A MY 184103 A MY184103 A MY 184103A
Authority
MY
Malaysia
Prior art keywords
expression
integration sites
enhanced
eukaryotic
novel cho
Prior art date
Application number
MYPI2017701254A
Other languages
English (en)
Inventor
Ying Shen
Darya Burakov
Gang Chen
James P Fandl
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54602002&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MY184103(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MY184103A publication Critical patent/MY184103A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
MYPI2017701254A 2014-10-23 2015-10-21 Novel cho integration sites and uses thereof MY184103A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462067774P 2014-10-23 2014-10-23
PCT/US2015/056653 WO2016064999A1 (en) 2014-10-23 2015-10-21 Novel cho integration sites and uses thereof

Publications (1)

Publication Number Publication Date
MY184103A true MY184103A (en) 2021-03-18

Family

ID=54602002

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2017701254A MY184103A (en) 2014-10-23 2015-10-21 Novel cho integration sites and uses thereof

Country Status (16)

Country Link
US (5) US9816110B2 (cg-RX-API-DMAC7.html)
EP (1) EP3209785B1 (cg-RX-API-DMAC7.html)
JP (1) JP6668340B2 (cg-RX-API-DMAC7.html)
KR (1) KR102243243B1 (cg-RX-API-DMAC7.html)
CN (1) CN107109434A (cg-RX-API-DMAC7.html)
AR (1) AR102420A1 (cg-RX-API-DMAC7.html)
AU (1) AU2015335921B2 (cg-RX-API-DMAC7.html)
BR (1) BR112017008022A2 (cg-RX-API-DMAC7.html)
CA (1) CA2965495C (cg-RX-API-DMAC7.html)
EA (1) EA037255B1 (cg-RX-API-DMAC7.html)
IL (1) IL251674B (cg-RX-API-DMAC7.html)
MX (1) MX2017005306A (cg-RX-API-DMAC7.html)
MY (1) MY184103A (cg-RX-API-DMAC7.html)
SG (1) SG11201703149RA (cg-RX-API-DMAC7.html)
TW (2) TWI747808B (cg-RX-API-DMAC7.html)
WO (1) WO2016064999A1 (cg-RX-API-DMAC7.html)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201703149RA (en) 2014-10-23 2018-02-27 Regeneron Pharma Novel cho integration sites and uses thereof
US10329594B1 (en) 2015-09-03 2019-06-25 CHO Plus, Inc. Cell lines for high level production of protein-based pharmaceuticals
US11649449B2 (en) 2015-09-03 2023-05-16 CHO Plus, Inc. Hybrid cell lines for high level production of a target protein
SG10202010156XA (en) 2016-04-20 2020-11-27 Regeneron Pharma Compositions and methods for making antibodies based on use of an expression-enhancing locus
EP3445781A1 (en) 2016-04-20 2019-02-27 Regeneron Pharmaceuticals, Inc. Compositions and methods for making antibodies based on use of expression-enhancing loci
EP3504328A1 (en) 2016-08-24 2019-07-03 Regeneron Pharmaceuticals, Inc. Host cell protein modification
JP2020501593A (ja) * 2016-12-20 2020-01-23 ディベロップメント センター フォー バイオテクノロジーＤｅｖｅｌｏｐｍｅｎｔ Ｃｅｎｔｅｒ Ｆｏｒ Ｂｉｏｔｅｃｈｎｏｌｏｇｙ 改変細胞、調製方法、及び構築物
WO2018148196A1 (en) * 2017-02-07 2018-08-16 Sigma-Aldrich Co. Llc Stable targeted integration
JP7637470B2 (ja) * 2017-02-17 2025-02-28 ロンザ リミテッド アデノ随伴ウイルスを生産するための哺乳動物細胞
WO2018175153A1 (en) * 2017-03-19 2018-09-27 Applied Stemcell, Inc. Novel integration sites and uses thereof
AU2018315428B2 (en) 2017-08-11 2024-11-14 Boehringer Ingelheim International Gmbh Integration sites in CHO cells
CN107723276B (zh) * 2017-11-02 2021-08-13 上海交通大学 一种稳定高表达目标产物的细胞株的构建方法和试剂盒
US20200318106A1 (en) * 2017-12-22 2020-10-08 Bio-Rad Laboratories, Inc. Controlling phenotype of organisms with crispr/cas gene targeting
IL275462B1 (en) * 2017-12-22 2025-09-01 Genentech Inc Targeted integration of nucleic acids
CN109295092B (zh) * 2018-10-30 2021-06-29 江南大学 一种cho细胞基因组内nw_003613638-1稳定表达蛋白质的应用
CN109337927B (zh) * 2018-10-30 2021-07-06 江南大学 一种cho细胞基因组内nw_006880285-1稳定表达蛋白质的应用
CN109295093B (zh) * 2018-10-30 2021-08-03 江南大学 一种cho细胞基因组内nw_006882456-1稳定表达蛋白质的应用
CN109207432B (zh) * 2018-10-30 2021-08-03 江南大学 一种cho细胞基因组内nw_006883358-1稳定表达蛋白质的应用
CN109136193B (zh) * 2018-10-30 2021-07-06 江南大学 一种cho细胞基因组内nw_006884764-1稳定表达蛋白质的应用
CN109321604B (zh) * 2018-10-30 2021-07-06 江南大学 一种cho细胞基因组内nw_006882077-1稳定表达蛋白质的应用
AU2019403279A1 (en) * 2018-12-21 2021-07-01 Genentech, Inc. Targeted integration of nucleic acids
SG11202110076PA (en) 2019-04-02 2021-10-28 Chugai Pharmaceutical Co Ltd Method of introducing target-specific foreign gene
EP3990649A1 (en) 2019-06-26 2022-05-04 Genentech, Inc. Randomized configuration targeted integration of nucleic acids
EP3901266A1 (en) * 2020-04-22 2021-10-27 LEK Pharmaceuticals d.d. Super-enhancers for recombinant gene expression in cho cells
CN116134136A (zh) * 2020-06-02 2023-05-16 康泰伦特药物解决方案有限责任公司 具有多个用于基因插入的Dock的细胞系
CA3172453A1 (en) * 2020-06-24 2021-12-30 Amy Shen Targeted integration of nucleic acids
EP4229205B1 (en) 2020-10-15 2025-05-14 F. Hoffmann-La Roche AG Nucleic acid constructs for va rna transcription
CN113755447B (zh) * 2021-09-23 2022-04-29 云舟生物科技(广州)股份有限公司 一种用于生产腺病毒的293a细胞株及其制备与应用
US20230287460A1 (en) 2021-10-18 2023-09-14 Regeneron Pharmaceuticals, Inc. Mammalian cells comprising integrated cas9 genes to produce stable integration sites, and mammalian cells comprising stable integration sites and other sites
KR20240099288A (ko) 2021-10-18 2024-06-28 리제너론 파마슈티칼스 인코포레이티드 아데노바이러스-연관 바이러스 폴리뉴클레오티드를 포함하는 진핵세포
TW202330926A (zh) 2021-10-18 2023-08-01 美商再生元醫藥公司 聚核苷酸之受控制轉錄
JP2025503925A (ja) * 2022-01-28 2025-02-06 ザ・トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク 異種移植のための遺伝子改変
CN117305334B (zh) * 2022-06-21 2024-11-08 深圳太力生物技术有限责任公司 靶向整合细胞及其制备方法、生产目标基因表达产物的方法
TW202434888A (zh) 2022-11-18 2024-09-01 美商再生元醫藥公司 用於偵測及測定包括生物流體在內之流體中之蛋白質結構及穩定性的方法
CN118726475B (zh) * 2023-03-28 2025-07-08 深圳太力生物技术有限责任公司 核酸、重组载体、靶向整合细胞、基因表达方法和应用
WO2024211287A1 (en) * 2023-04-03 2024-10-10 Seagen Inc. Production cell lines with targeted integration sites
US20250122482A1 (en) 2023-09-07 2025-04-17 Regeneron Pharmaceuticals, Inc. Production and purification of covalently surface modified adeno-associated virus
WO2025111473A1 (en) 2023-11-21 2025-05-30 Regeneron Pharmaceuticals, Inc. Covalently surface modified adeno-associated virus production by in vitro conjugation, and purification of covalently surface modified adeno-associated virus

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4656134A (en) 1982-01-11 1987-04-07 Board Of Trustees Of Leland Stanford Jr. University Gene amplification in eukaryotic cells
ATE539161T1 (de) 1998-07-21 2012-01-15 Millipore Corp Ein ein allgegenwärtiges chromatin-öffnendes element (ucoe) enthaltendes polynucleotid
US6521419B1 (en) * 1998-09-22 2003-02-18 Kanakaraju Koduri Expression vectors containing hot spot for increased recombinant protein expression in transfected cells
WO2002081632A2 (en) 2001-04-04 2002-10-17 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Nucleic acids for transgene expression
US20040045043A1 (en) * 2002-05-20 2004-03-04 Finney Robert E. Compositions and methods for generating conditional knockouts
US8673589B2 (en) 2002-05-29 2014-03-18 Regeneron Pharmaceuticals, Inc. Inducible eukaryotic expression system
EP2150617B1 (en) 2007-06-04 2014-10-22 Regeneron Pharmaceuticals, Inc. Enhanced expression and stability regions
CA2745031C (en) * 2008-12-04 2018-08-14 Sangamo Biosciences, Inc. Genome editing in rats using zinc-finger nucleases
CN105969807A (zh) 2011-04-05 2016-09-28 斯克利普斯研究所 染色体着陆垫及相关用途
EP3403672A1 (en) 2011-04-20 2018-11-21 Medlmmune, LLC Antibodies and other molecules that bind b7-h1 and pd-1
WO2012167192A2 (en) * 2011-06-01 2012-12-06 Precision Biosciences, Inc. Methods and products for producing engineered mammalian cell lines with amplified transgenes
AU2012328682B2 (en) * 2011-10-27 2017-09-21 Sangamo Therapeutics, Inc. Methods and compositions for modification of the HPRT locus
AU2013259647B2 (en) 2012-05-07 2018-11-08 Corteva Agriscience Llc Methods and compositions for nuclease-mediated targeted integration of transgenes
SG11201703149RA (en) 2014-10-23 2018-02-27 Regeneron Pharma Novel cho integration sites and uses thereof

Also Published As

Publication number Publication date
KR102243243B1 (ko) 2021-04-22
AU2015335921A1 (en) 2017-05-04
EA201790698A1 (ru) 2018-01-31
EA037255B1 (ru) 2021-02-26
BR112017008022A2 (pt) 2018-02-20
US20240018553A1 (en) 2024-01-18
US11268109B2 (en) 2022-03-08
US11788102B2 (en) 2023-10-17
US20160115502A1 (en) 2016-04-28
WO2016064999A1 (en) 2016-04-28
JP6668340B2 (ja) 2020-03-18
US20210171984A1 (en) 2021-06-10
AR102420A1 (es) 2017-03-01
KR20170096999A (ko) 2017-08-25
CA2965495A1 (en) 2016-04-28
TW201629229A (zh) 2016-08-16
EP3209785A1 (en) 2017-08-30
IL251674B (en) 2020-10-29
TW202144576A (zh) 2021-12-01
MX2017005306A (es) 2018-01-09
EP3209785B1 (en) 2019-07-31
CN107109434A (zh) 2017-08-29
US20200002732A1 (en) 2020-01-02
US20180030480A1 (en) 2018-02-01
CA2965495C (en) 2022-05-24
TWI747808B (zh) 2021-12-01
JP2017535258A (ja) 2017-11-30
US9816110B2 (en) 2017-11-14
SG11201703149RA (en) 2018-02-27
IL251674A0 (en) 2017-06-29
TWI780847B (zh) 2022-10-11
AU2015335921B2 (en) 2020-06-25

Similar Documents

Publication Publication Date Title
MY184103A (en) Novel cho integration sites and uses thereof
CY1124627T1 (el) Στοχευμενη τροποποιηση γονιδιωματος αρουραιου
BR112016025519A2 (pt) engenharia genética in vivo com vetores de adenovírus
MX2025009055A (es) Vectores de neoantigeno de alfavirus
ZA202310779B (en) Compositions and methods for enhanced gene expression
PH12019501130A1 (en) Viral delivery of neoantigens
EP4249074A3 (en) Genomic engineering of pluripotent cells
MX2021014712A (es) Polipeptidos de transposasa y sus usos.
MX2017011255A (es) Sistema de vector múltiple y sus usos.
MX388127B (es) Metodos y composiciones para la modificacion dirigida de un genoma.
WO2017106537A3 (en) Targeted disruption of the mhc cell receptor
WO2015157579A3 (en) Enhanced nucleic acid constructs for eukaryotic gene expression
EP4303232A3 (en) Chimeric antigen receptor and methods of use thereof
MX2020004541A (es) Edicion de genes de celulas primarias.
MX382223B (es) Regulacion de expresion genica mediada por nucleasa.
MX2018001617A (es) Composiciones de crispr-cas9 diseñados y metodos de uso.
WO2016057951A3 (en) Crispr oligonucleotides and gene editing
MX2017014125A (es) Variantes de alfa-amilasa y polinucleotidos que codifican las mismas.
MX353134B (es) Ratones con receptor de linfocitos t modificados geneticamente.
MX2014012994A (es) Direccion transmitida por nucleasa con vectores de direccion grandes.
MX388784B (es) Métodos y composiciones para la modificación genética dirigida a través de direccionamiento múltiple de una sola etapa.
EP3237613A4 (en) Visualizing modified nucleotides and nucleic acid interactions in single cells
AU2017250265A1 (en) Methods for creating synthetic chromosomes having gene regulatory systems and uses thereof
EP3964575A3 (en) Alpha-amylase variants and polynucleotides encoding same
WO2018144087A3 (en) Dna plasmids for the fast generation of homologous recombination vectors for cell line development